Taxotere (Docetaxel)

Taxotere litigation, centered on claims that the chemotherapy drug docetaxel causes permanent alopecia, meaning hair that does not regrow after chemotherapy ends, is now a smaller, more mature docket, with 81 actions still coordinated in the Eastern District of Louisiana roughly a decade after centralization. That scale reflects a docket that has moved substantially through bellwether trials and case-specific resolution rather than one still in its claim-building phase.

The injury theory here is distinctive within oncology-drug litigation: plaintiffs are cancer survivors, not patients harmed by a failed cancer treatment, alleging a permanent cosmetic and psychological injury from inadequate warning about a known risk of the chemotherapy regimen itself. That framing affects damages modeling, since claims typically do not involve additional physical treatment costs beyond the cancer treatment already received, but do involve real, often significant, psychological and quality-of-life damages tied to permanent hair loss.

Medical-lien exposure in this docket is generally more limited than in a docket built around a new physical injury requiring its own separate treatment, since the underlying cancer treatment was medically necessary and not itself the alleged wrong; liens, where they exist, are more likely tied to any psychological-care treatment a claimant pursued. For a firm with a remaining Taxotere inventory, portfolio finance against that book, priced with attention to individual diagnosis timing and warning-label history, is a reasonable structure given the claim type's relative consistency. Where a bellwether verdict pattern has already emerged, funding structures can price duration risk against that established record rather than an open bellwether calendar, which is a meaningful advantage relative to a docket still selecting its first trial pool.

Criterica Capital's mass tort finance product is suited to this kind of claim. A structural read on the docket's current bellwether and settlement posture is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.